Publications

Key Articles:

  • Perispinal etanercept advances as a neurotherapeutic. Edward Tobinick MD, Expert Review Neurotherapeutics, 2018:1-3. (Free Download).
  • Perispinal Etanercept for Traumatic Brain Injury. Edward Tobinick MD, Rodriguez-Romanacce H, Kinssies R, Kim N. Chapter 7, pp. 109-29, in New Therapeutics for Traumatic Brain Injury, KA Heidenreich, editor. Cambridge, Mass.: Academic Press. 2017. (Link to Book Chapter).
  • On Overcoming Barriers to Application of Neuroinflammation Research. Edward Tobinick MD, Ignatowski, T., Spengler, R. In: Abreu GEA, ed. Mechanisms of Neuroinflammation: InTechOpen; 2017. (Free Download).
  • Perispinal Delivery of CNS Drugs.  Edward Tobinick MD.  CNS Drugs, 2016;30(6):469-80. (Free Download).
  • Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence. Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E. CNS Drugs, August 2014, 28(8):679-697, published online 27 May 2014. (Free Download).
  • Immediate Neurological Recovery Following Perispinal Etanercept Years After Brain Injury. Edward Tobinick MD, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Clin Drug Investig. 2014 May;34(5):361-6. (Link to Journal Article).
  • Studies of Selective TNF Inhibitors in the Treatment of Brain Injury From Stroke and Trauma: A Review of Evidence to Date. Tuttolomondo, A., R. Pecoraro, and A. Pinto, Drug Design, Development and Therapy, 2014(November). 8: p. 2221-2239. (Free Download).
  • New Hope for Survivors of Stroke and Traumatic Brain Injury. Clark, I., CNS Drugs, 2012. 26(12): p. 1071-2; (Free Download).
  • Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury – An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept. Edward Tobinick MD, Kim NM, Reyzin G, Rodriguez H, DePuy V. CNS Drugs. 2012 Dec;26(12):1051-70. (Link to Journal Article).
  • Rapid Improvement of Chronic Stroke Deficits After Perispinal Etanercept: Three Consecutive Cases. Edward Tobinick MD. CNS Drugs. 2011 Feb 1; 25(2):145-155. (Link to Journal Article).
  • Perispinal Etanercept: A New Therapeutic Paradigm in Neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002. (Free Download).

Selected Additional INR Scientific Publications:

  • Authors’ Reply to Whitlock: Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence. Ignatowski TA, Spengler RN, Tobinick E. CNS Drugs, December 2014, 28(12):1207-13. (Free Download).
  • Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research 2012, 9:99-109. (Free Download).
  • Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. Edward Tobinick MD, K Chen PhD, X Chen PhD. BMC Res Notes. 2009 Feb 27;2:28. (Free Download).
  • Perispinal etanercept for neuroinflammatory disorders. Edward Tobinick MD. Drug Discovery Today. 2009 Feb;14(3-4):168-77. (Full Text Link).
  • Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Edward Tobinick MD. Medscape J Med. 2008 Jun 10;10(6):135. (Full Text Link).
  • Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H. Gross MD. BMC Neurology. 2008 Jul 21;8:27. (Free Download).
  • Perispinal Etanercept: Potential as An Alzheimer Therapeutic. Griffin WS. J Neuroinflammation. 2008 Jan 10;5:3. (Free Download).
  • Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Edward Tobinick MD, Hyman Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2. (Free Download).
  • The cerebrospinal venous system: anatomy, physiology, and clinical implications. Edward Tobinick MD. MedGenMed. 2006 Feb 22;8(1):53. (Link to Journal Article).
  • Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Edward Tobinick MD, Davoodifar S. Curr Med Res Opin. 2004 Jul;20(7):1075-85. (Link to Journal Article).
  • Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Edward L. Tobinick MD. Clinical Therapeutics. 2003 Aug;25(8):2279-88. (Link to Journal Article).
 Recent publications by independent academic scientists:
  • Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agentsClark, I.A. and B. Vissel. Journal of Neuroinflammation (2016) 13:236. (Free Full Text).
  • Treatment of traumatic brain injury with anti-inflammatory drugs. Bergold Peter J. Experimental Neurology 275 (Pt 3) (2016) 367-380. (Full Text Link).
  • Inflammatory Cytokine Receptor Blocade in a Rodent Model of Mild Traumatic Brain Injury. Perez-Polo JR, Rea HC, Johnson KM, Parsley MA, et. al. Journal of Neuroscience Research 94: 27-38 (2016). (Free Download).
  • Cerebral stroke injury: the role of cytokines and brain inflammation. Siniscalchi, A., Gallelli, L., Malferrari, G., Pirritano, D. et. al. J Basic Clin Physiol Pharmacy. 2014 May 1; 25(2):131-7. 2016:14(1):98-105. (Full Text Link).
  • A Neurologist’s Guide to TNF biology, and to the principles behind the therapeutic removal of excess TNF in disease. Clark IA, B Vissel. Neural Plasticity, Volume 2015, Article ID 358263, http://dx.doi.org/10.1155/2015/358263. (Free Download).
  • Action of anti-TNF-alpha drugs on the progression of Alzheimer’s disease: A case report. Carlos Henrique Ferreira Camargo, FF Justus, G Uretzlaff, MRY Blood, MD Schafranski.  Dementia & Neuropsychoelogia. 9(2) April/June 2015. http://dx.doi.org/10.1590/1980-57642015DN92000015. (Free Download).
  • Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. Clausen, B., M. Degn, N. Martin, et al., J Neuroinflammation, 2014. 11(1): p. 203. (Free Download).
  • Etanercept Alleviates Early Brain Injury Following Experimental Subarachnoid Hemorrhage and the Possible Role of Tumor Necrosis Factor-alpha and c-Jun N-Terminal Kinase Pathway. Zhang, B., J. Song, X. Ma, et al., Neurochem Res, 2014. epub 2014 Dec 27. (Link to Journal Article).
  • Targeting TNF: a therapeutic strategy for Alzheimer’s disease. Cheng X, Shen Y, Li R. Drug Discovery Today. 2014:19(11):1822-7. (Full Text Link).
  • Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Olmos G, Llado J. Mediators Inflamm. 2014;2014:861231. (Free Download).
  • Immunology primer for neurosurgeons and neurologists part 2: Innate brain immunity. Blaylock RL. Surg Neurol Int. 2013;4:118. (Free Download).

Additional scientific articles:

  •  The vertebral vein system. Caldwell lecture, 1956. Batson OV. Am J Roentgenol Radium Ther Nucl Med. 1957;78(2):195-212. (Link to Journal Article).
  • The craniospinal venous system. Pearce JM. Eur Neurol. 2006;56(2):136-8. (Free Full Text).
  • History of the vertebral venous plexus and the significant contributions of Breschet and Batson. Nathoo N, Caris EC, Wiener JA, Mendel E. Neurosurgery. 2011;69(5):1007-14; discussion 14. (Link to Journal Article).
  • Venous Drainage of the Spine and Spinal Cord: A Comprehensive Review of its History, Embryology, Anatomy, Physiology, and Pathology. Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M, Tubbs RS. Clinical Anatomy. 2014;epub. (Link to Journal Article).
  • Randomized, Double-blind, Placebo-Controlled, Trial of Transforaminal Epidural Etanercept for the Treatment of Symptomatic Lumbar Disc Herniation.  Freeman, B.J., et. al. Spine (Phila Pa 1976), 2013. 38(23): p. 1986-94.(Link to Journal Article).
  • Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine (Phila Pa 1976), 2012. 37(6): p. 439-44. Ohtori, et. al. (Link to Journal Article).
  • Therapeutic evaluation of etanercept in a model of traumatic brain injury. Chio CC, Lin JW, Chang MW, Wang CC, Kuo JR, Yang CZ, Chang CP. J Neurochem. 2010 Nov;115(4):921-9. (Link to Journal Article).
  • Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. Frankola KA, Greig NH, Luo W, Tweedie D. CNS Neurol Disord Drug Targets. 2011 Feb 2. (Free Full Text).
  • Anti-TNF therapy in the injured spinal cord. Esposito E, Cuzzocrea S. Trends Pharmacol Sci. 2011 Feb;32(2):107-15. Epub 2010 Dec 23. (Link to Journal Article).
  • Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, Wong CS. Anesth Analg. 2011 Feb;112(2):454-9. (Link to Journal Article).
  • Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, Zhu HQ, Zhang QQ, Zhang YD, Xu J. Brain Res. 2011 Jan 12;1368:239-47. (Link to Journal Article).
  • Attenuation of Inflammatory Events in Human Intervertebral Disc Cells with a Tumor Necrosis Factor Antagonist. Sinclair SM, Shamji MF, Chen J, Jing L, Richardson WJ, Brown CR, Fitch RD, Setton LA. Spine (Phila Pa 1976). 2011 Jan 6. (Free Full Text).
  • Intrathecal inflammation precedes development of Alzheimer’s disease. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5. (Free Full Text).
  • Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Park KM, Bowers WJ. Cell Signal. 2010 Jul;22(7):977-83. (Free Full Text).
  • The roles of TNF in brain dysfunction and disease. Clark IA, Alleva LM, Vissel B. Pharmacol Ther. 2010 Dec;128(3):519-48. (Link to Journal Article).
  • An association study of 21 potential Alzheimer’s disease risk genes in a Finnish population. Sarajärvi T, Helisalmi S, Antikainen L, Mäkinen P, Koivisto AM, Herukka SK, Haapasalo A, Soininen H, Hiltunen M. J Alzheimers Dis. 2010;21(3):763-7. (Link to Journal Article).
  • The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Medeiros R, Figueiredo CP, Pandolfo P, Duarte FS, Prediger RD, Passos GF, Calixto JB. Behav Brain Res. 2010 May 1;209(1):165-73. (Link to Journal Article).
  • Soluble TNF receptors are associated with A-beta metabolism and conversion to dementia in subjects with mild cognitive impairment. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Neurobiol Aging. 2010 Nov;31(11):1877-84. (Link to Journal Article).
  • Inflammation and anti-inflammatory strategies for Alzheimer’s disease–a mini-review. McNaull BB, Todd S, McGuinness B, Passmore AP. Gerontology. 2010;56(1):3-14. (Free Full Text).
  • Systemic inflammation and disease progression in Alzheimer disease. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH. Neurology. 2009 Sep 8;73(10):768-74. (Free Full Text).
  • Paths to acceptance. The advancement of scientific knowledge is an uphill struggle against ‘accepted wisdom’. Wolinsky H. EMBO Rep. 2008 May;9(5):416-8. (Free Full Text).